Journal of Chinese Pharmaceutical Sciences ›› 2019, Vol. 28 ›› Issue (4): 238-246.DOI: 10.5246/jcps.2019.04.024

• Original articles • Previous Articles     Next Articles

IMB-XH1 identified as a novel inhibitor of New Delhi metallo-β-lactamase-1

Jiangxue Han1, Chunling Xiao1, Maoluo Gan1, Xinghua Li1, Ying Wang1, Jiayin Zheng2, Dongsheng Li1, Chennan Liu1, Yan Guan1, Jianzhou Meng1, Shuchao Huang1, Yishuang Liu1*   

  1. 1. National Key Laboratory for Screening New Microbial Drugs, Institute of Medicinal Biotechnology, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100050, China
    2. Department of Neurobiology, Capital Medical University, Beijing 100069, China
  • Received:2019-02-11 Revised:2019-03-11 Online:2019-04-30 Published:2019-03-14
  • Contact: Tel.: +86-010-63020226, E-mail:
  • Supported by:

    Natural Sciences Foundation of China (NSFC, Grant No. 81872913), the CAMS Initiative for Innovative Medicine (Grant No.2016-I2M-1-013), the Fundamental Research Funds for Central Public-interest Scientific Institution (Centre for Tuberculosis) (Grant No. 2016ZX310183-3) and the National High-tech R&D Program (863 Program, Grant No. 2015AA020911).


The problem of drug resistance of Gram-negative bacteria has become increasingly serious and has aroused widespread public concern. The super bacteria producing New Delhi metallo-beta-lactamase (NDM-1) are resistant to almost all β-lactam antibiotics. However, clinically existing β-lactamase inhibitors are ineffective against metallo-β-lactamases (MBLs) including NDM-1. Therefore, effective NDM-1 inhibitors are urgently needed. In this study, a high-throughput screening model for NDM-1inhibitors was optimized and used to screen NDM-1 inhibitors. As a result, IMB-XH1 was screened out as a novel NDM-1 inhibitor from 52 100 compounds of different sources. The combined use of IMB-XH1 can increase the sensitivity of E. coli BL21(DE3) (pET-30a(+)-NDM-1) to β-lactam antibiotics. Enzymatic kinetic studies indicate that IMB-XH1 is a non-competitive inhibitor of NDM-1 and also has inhibitory activity against other MBLs such as IMP-4, ImiS and L1. As a novel NDM-1 inhibitor, its activity and mechanism of action need to be further explored.  

Key words: NDM-1, Metallo-β-lactamases inhibitor, High throughput screening, Bacterial resistance

CLC Number: